Form4insider filings, from the source

SEC Form 4 · accession 0000919574-17-006370

Avalo Therapeutics, Inc. · AVTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
ARMISTICE CAPITAL, LLC
Director · 10% Owner
Steven Boyd
10% Owner
Period of report
Aug 22, 2017
Accepted (ET)
Aug 24, 2017 · 5:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1Aug 22, 2017P19,301$0.6163A15,734,865D
Common StockF2Aug 22, 2017P19,301$0.6163A15,734,865ISee Footnote
Common StockF2Aug 22, 2017P19,301$0.6163A15,734,865ISee Footnote
Common StockF1Aug 23, 2017P900$0.6186A15,735,765D
Common StockF2Aug 23, 2017P900$0.6186A15,735,765ISee Footnote
Common StockF2Aug 23, 2017P900$0.6186A15,735,765ISee Footnote
Common StockF1Aug 24, 2017P19,944$0.6991A15,755,709D
Common StockF2Aug 24, 2017P19,944$0.6991A15,755,709ISee Footnote
Common StockF2Aug 24, 2017P19,944$0.6991A15,755,709ISee Footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
WARRANTSF1,F3$0.40holding————Jun 30, 2022COMMON STOCK14,285,71414,285,714D
WARRANTSF2,F3$0.40holding————Jun 30, 2022COMMON STOCK14,285,71414,285,714I
WARRANTSF2,F3$0.40holding————Jun 30, 2022COMMON STOCK14,285,71414,285,714I

Explanation of responses